Influenza Vaccination: Safe and **Proven to Help Protect Pregnant Women and Infants**

Pregnant women are more at risk for severe outcomes from influenza infection¹⁻⁵



Rising rates of maternal obesity, increasing age, and more chronic comorbid conditions may contribute to the risk of severe maternal morbidity due to influenza45

In a nationwide inpatient sample from 2000-2018, pregnant women with an influenza diagnosis at delivery were ~2x as likely to experience severe maternal morbidity such as sepsis, shock, mechanical intubation, ARDS, and death²

Pregnant women in their 3rd trimester were 3-4X more likely to be hospitalized with cardiopulmonary illness during influenza season compared to post-partum women³

Pregnant women with comorbid conditions* were 3x more likely to be hospitalized for respiratory illness during influenza season than women without these comorbid conditions³

*chronic cardiac disease, chronic pulmonary disease, diabetes mellitus, chronic renal disease, malignancies, and

SONO




Pregnant women were more than 2x as likely to be admitted to the hospital with influenza than nonpregnant women⁴



Infants/young children are also at increased risk from influenza infection⁶

Average number of influenza-associated hospitalizations per 100,000 children aged 0-23 months Influenza Hospitalization Surveillance Network (FluSurv-NET), United States, 2010-11 through 2017-18 influenza seasons



- Annual influenza vaccination is recommended for persons ≥6 months of age¹ Despite recommendations,
- vaccination coverage rate in pregnant persons has declined annually7

ACIP and ACOG recommend that persons who are pregnant or who might be pregnant or postpartum during the influenza season receive influenza vaccine^{1,8}




Any licensed recommended, and age appropriate IIV or RIV may be used



LAIV4 should not be used during pregnancy but can be used in eligible persons postpartum



Early vaccination (i.e. July and August) can be considered for persons who are in the 3rd trimester during these months



New data supports safety of recombinant influenza vaccine in pregnant women⁹

Background

- Large, observational safety surveillance study to assess safety of RIV4 during pregnancy
- All vaccinated pregnant women were a subset of a separate, cluster randomized effectiveness trial of ~1.6 million eligible Kaiser Permanente Northern California (KPNC) members
- Included ~48,000 routinely influenza-vaccinated pregnant women and their live born infants at KPNC during 2 influenza seasons (2018/19, 2019/20)



Primary objective

Evaluate the safety of quadrivalent recombinant influenza vaccine (RIV4) compared with quadrivalent inactivated influenza vaccine (SD-IIV4) in pregnant women and their offspring

Baseline characteristics

Table 1. Trimester demographics of pregnant women

The demographics (age, race, ethnicity, comorbidity, trimester) of the pregnancy cohort were well balanced (Table 1 *) *not all demographic results are provided	Trimester of vaccination	RIV4 N=14,981; n (%)	SD-IIV4 N=33,800; n (%)
	1 st Trimester	5,092 (34.0)	10,787 (31.9)
	2 nd Trimester	4,851 (32.4)	11,470 (33.9)
	3rd Trimester	4 288 (28 6)	10 176 (30 1)

Results

• Within a large population of pregnant women, there were no differences in pregnancy, birth, and neonatal/infant outcomes with RIV4 compared to SD-IIV4 for

ifluenza vaccination (Table 2)

• No safety concerns were identified with RIV4 use in pregnancy

Table 2. Birth/infant outcomes

Outcome	RIV4 N=14,538; n (%)	SD-IIV4 N=32,856; n (%)	Adjusted OR (95% Cl)*
Birth			
Preterm birth	1,061 (7.3)	2,450 (7.5)	0.98 (0.91, 1.05)
Low birth weight	852 (5.9)	1,918 (5.8)	1.00 (0.92, 1.09)
Small for gestational age	1,277 (8.8)	2,846 (8.7)	1.01 (0.94, 1.09)
Infant (up to 365 days)			
Infant death	27 (0.2)	59 (0.2)	1.05 (0.66, 1.65)
Congential anomalies	6,259 (43.1)	14,018 (42.7)	1.01 (0.97, 1.05)
 Major congential anomalies 	1,113 (7.7)	2,531 (7.7)	N/C
 Minor congential anomalies 	5,698 (39.2)	12,762 (38.8)	N/C
Failure to thrive	150 (1.0)	372 (1.1)	0.90 (0.75, 1.09)

'SD-IIV4 was the reference group for all analysis, logistic regressions adjusted for infant sex, infant race, infant ethnicity, maternal age group, and maternal trimester of influenza vaccine receipt. N/C; not conducted

Q

Limitations

Imbalances in the quantity of RIV4 versus SD-IIV4 administered to pregnant women may have been attributed to provider preference once they knew an individual was pregnant, availability of either vaccine, or other factors affecting realworld studies

The results of this study in 48,781 pregnant women support the current ACIP recommendation for the use of inactivated/recombinant influenza vaccine in this 'at risk' population



Abbreviations

ACCG, American College of Obstetricians and Gynecologists; ARDS, acute respiratory distress syndrome; ACIP, advisory committee on immunization practices; OR, odds ratio; CI, confidence interval; LAIV4, live attenuated quadrivalent influenza vaccine; IIV, inactivated influenza vaccine; IIV4, quadrivalent influenza vaccine; IV4, quadrivalent influ

References

- repreners: Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines; Recommendations of the Advisory Committee on Immunization Practices-United States, 2023-24 Influenza Season. MMWR Recomm Rep 2023;72 (No. RR-2):1-25. https://www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm?s_cid=rr7202a1w, Accessed 9 OCT 2024. Wen T, et al. Influenza Complicating Delivery Hospitalization and Its Association with Severe Maternal Morbidity in the United States, 2000-2018. Obstet & Gynecol. 2021. 138(2): 218-27. DOI:10.1097/AOG.000000000004462.
- Rassumsen SA et al. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol. Sep 2012;207(3 Suppl):S3-8. DOI:10.1016/j.ajog.2012.06.068.
- Metz D, et al. Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. Vaccine 2017. 35 (4):521-8. 10.1016/j.vaccine.2016.12.012. Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012;12:1029–36. DOI: 10.1097/AGG.060013e31826d605. J Unidey MC, et al. Vital Sgriss Eurode and Pervesita Manna Perussia Kannag Pregnant Women and Infants United States I. MAVMR Morb Mortal Wki Rep 2019;88:885-92. 0c5. Accessed 18 APR 2024.
- DOI: http://dx.doi.org/10.15585/mmwr.mm6840e1 Accessed 9 OCT 2024.
- Centers of Disease Control and Prevention. Influenza (Itu). Influenza Vaccination Coverage, Pregnant Persons, United States. Influenza Vaccination Coverage Among Pregnant Persons, United States (cdc.gov). Accessed 9 OCT 2024. Influenza in Pregnancy: Prevention and Treatment. Influenza in Pregnancy: Prevention and Treatment: ACOG Committee Statement No. 7. Obstet & Gynecol. 2024 Feb 1;143(2):e24-e30. DOI:10.1097/AOG. 000000000005479. PMID/30016515. Accessed 5 APR 2024.
- 9. Hsiao A et al. Safety of quadrivalent recombinant influenza vaccine in pregnant women and their infants. AJOG Global Reports. 2024 Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants ScienceDirect doi:https://doi.org/10.1016/j.xagr.2024.100395 Accessed 9 OCT 2024.

©2024 Sanofi. All rights reserved MAT-US-2400050 v2.0 - P EXP: 21 OCT 2025

